TY - JOUR AU - ANWAR, EFFIONORA AU - SHERMAN, JESSICA RAMADHANTY VALENSYA PY - 2020/03/23 Y2 - 2024/03/29 TI - FORMULATION OF ENTERIC GRANULES CONTAINING GREEN TEA (CAMELLIA SINENSIS) EXTRACT USING EUDRAGIT L100-55 AS A DELAYED RELEASE MATRIX JF - International Journal of Applied Pharmaceutics JA - Int J App Pharm VL - 12 IS - 1 SE - Original Article(s) DO - 10.22159//ijap.2020.v12s1.FF028 UR - https://journals.innovareacademics.in/index.php/ijap/article/view/37552 SP - 126-129 AB - <p><strong>Objective</strong>: Epigallocatechin gallate (EGCG) inhibits glucose absorption into the blood by inhibiting small intestinal α-glucosidase but is unstable in<br>gastric fluid. Hence, we formulated EGCG into enteric preparations that prevent release in gastric fluid.<br><strong>Methods</strong>: Granules were prepared using a wet granulation method and were formulated into polyvinylpyrrolidone (PVP)-Eudragit L100-55 (5:1; F1),<br>PVP-Eudragit L100-55 (1:1; F2), and Eudragit L100-55 (F3) preparations using 30% w/w Eudragit L100-55 as a matrix. EGCG contents of granules<br>were evaluated and dissolution tests were performed at pH 1.2 and 6.8.<br><strong>Results</strong>: F1–3 formulas had good flow properties and contained EGCG at 24.05%±0.15%–24.96%±0.28%. Dissolution tests showed that F1 and F2<br>formulas released EGCG at 50.53%±0.04% and 17.80%±0.55%, respectively, after 2 h in HCl medium at pH 1.2. Cumulative drug release from F1 and<br>F2 formulations after 2 h under these conditions (pH 1.2) and 1 h in phosphate buffer (pH 6.8) was 94.40%±1.58% and 93.70%±1.08%, respectively.<br><strong>Conclusion</strong>: As the optimal formula, F3 granules limited drug release to 7.03%±0.22% in HCl at pH 1.2 over 2 h and cumulative drug release in HCl<br>medium (pH 1.2) followed by phosphate buffer (pH 6.8) of 86.13%±0.20%.</p> ER -